AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
durlobactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 5731 | 1467829-71-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor, that protects sulbactam from degradation by certain serine-beta-lactamases. Durlobactam alone does not have antibacterial activity against Acinetobacter baumannii-calcoaceticus complex (ABC) isolates but in combination with sulbactam it has been approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.545 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.764 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.200 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.718 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 74.560 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 66.100 | % | High | 1 |
| herg | hERG pIC50 | 4.065 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.047 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 4.592 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 76.270 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PRKDC,SYK,TEK | 20 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EPHB4,ERBB2,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 | 15 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.254 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 3.724 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 84.030 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.308 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 69.710 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.629 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 94.840 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 72.410 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 845.279 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 23, 2023 | FDA | ENTASIS THERAP |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CG30 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| FDA MoA | N0000000202 | beta Lactamase Inhibitors |
| FDA EPC | N0000175930 | beta Lactamase Inhibitor |
| CHEBI has role | CHEBI:35625 | EC 3.5.2.6 (β-lactamase) inhibitor |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
Related Drugs by ATC class:
J01CG Beta-lactamase inhibitors 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex | indication | 429271009 | |
| Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex | indication | 445780006 | |
| Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex | indication | 1010634002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 9623014 | April 2, 2033 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 10376499 | Nov. 17, 2035 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 9968593 | Nov. 17, 2035 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | May 23, 2028 | NEW CHEMICAL ENTITY |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | May 23, 2033 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Betalactamase OXA24 | Enzyme | INHIBITOR | IC50 | 6.72 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 7.86 | SCIENTIFIC LITERATURE | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:229539 | CHEBI |
| CHEMBL4298137 | ChEMBL_ID |
| C000626193 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12693 | IUPHAR_LIGAND_ID |
| DB16704 | DRUGBANK_ID |
| 4042481 | VANDF |
| 4042482 | VANDF |
| C5420986 | UMLSCUI |
| CHEMBL4297378 | ChEMBL_ID |
| 10824 | INN_ID |
| 1467157-21-6 | SECONDARY_CAS_RN |
| 89851852 | PUBCHEM_CID |
| 368020 | MMSL |
| 41619 | MMSL |
| d10064 | MMSL |
| 019452 | NDDF |
| 019453 | NDDF |
| D11591 | KEGG_DRUG |
| PSA33KO9WA | UNII |
| 2639089 | RXNORM |
| C000714947 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None